<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04537442</url>
  </required_header>
  <id_info>
    <org_study_id>Immunochina</org_study_id>
    <nct_id>NCT04537442</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma</brief_title>
  <official_title>Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Immunochina Medical Science &amp; Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Immunochina Medical Science &amp; Technology Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center study to assess the efficacy and safety of IM21 CAR-T cells in adult&#xD;
      with R/R multiple myeloma in China.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, about 10 patients with relapsed or refractory multiple myeloma aged ≥60 years&#xD;
      were recruited for IM21 CAR-T cell single transfusion therapy. The safety and tolerability of&#xD;
      the treatment were evaluated, and the curative effect was initially observed. The research&#xD;
      plan includes five stages: screening stage, cell collection stage, chemotherapy pretreatment&#xD;
      stage, infusion stage and follow-up stage.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 3, 2020</start_date>
  <completion_date type="Anticipated">March 2, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events within 1 month after CAR-T cell infusion</measure>
    <time_frame>30days</time_frame>
    <description>The primary endpoint wasIncidence of adverse events within 1 month after CAR-T cell infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate(ORR) at 90 days</measure>
    <time_frame>90days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>IM21 CAR-T cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IM21 CAR-T cells administrated in a dosage to be selected by physician from a specific range.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IM21 CAR-T cells</intervention_name>
    <description>IM21 CAR-T cells&#xD;
Drug: Fludarabine&#xD;
Two days before cell infusion, all patients will be treated with fludarabine for 3 days&#xD;
Drug: Cyclophosphamide&#xD;
Two days before cell infusion, all patients will be treated with Cyclophosphamide for 3 days&#xD;
Other Names:&#xD;
Fludarabine Cyclophosphamide</description>
    <arm_group_label>IM21 CAR-T cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with relapsed or refractory multiple myeloma who had received at least second&#xD;
             line regular treatment failure;&#xD;
&#xD;
          2. Age ≥60 years old;&#xD;
&#xD;
          3. The expected survival time is more than 3 months;&#xD;
&#xD;
          4. ECOG score is 0-2;&#xD;
&#xD;
          5. Those who voluntarily participate in the study and sign the informed consent;&#xD;
&#xD;
          6. Hemoglobin (Hb)≥80g/L; Absolute count of neutrophils (ANC) &gt;1×10^9/L Total platelet&#xD;
             count (PLT)≥35×10^9/L;&#xD;
&#xD;
          7. left ventricular ejection fraction &gt; 45%.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. High-risk viscera-involved patients: the tumor invaded the gastrointestinal tract,&#xD;
             lung, pericardium and one of the great vessels;&#xD;
&#xD;
          2. Those who have graft versus host disease and need to use immunosuppressive agents;&#xD;
&#xD;
          3. Use of systemic steroids in combination within 5 days prior to the blood collection&#xD;
             period (except for recent or current use of inhaled steroids);&#xD;
&#xD;
          4. Active hepatitis B or C virus, HIV or other untreated active infected persons;&#xD;
&#xD;
          5. Any circumstance that, in the opinion of the investigator, may increase the risk to&#xD;
             the subject or interfere with test results;&#xD;
&#xD;
          6. Patients who use chemotherapy or radiotherapy within 3 days before the blood&#xD;
             collection stage.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hui Liu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fei Wu, MD</last_name>
    <phone>+8615801390058</phone>
    <email>wufei@immunochina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hui Liu, MD, PhD</last_name>
      <phone>13520618812</phone>
      <email>liuhui8140@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 28, 2020</study_first_submitted>
  <study_first_submitted_qc>August 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 3, 2020</study_first_posted>
  <last_update_submitted>August 28, 2020</last_update_submitted>
  <last_update_submitted_qc>August 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

